• Halozyme projected zero to minimal royalty revenue impact through at least 2035 from CMS’s June 12 draft Medicare Drug Price Negotiation rule for IPAY 2029.
• Outlook reflected its reading of the proposed rule’s treatment of orphan drug protections.
• Projection also factored in how biosimilar entry could affect a drug’s eligibility for the negotiation program.
• No expected effect on the ability to sign new ENHANZE partnership agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606150600PR_NEWS_USPR_____LA83235) on June 15, 2026, and is solely responsible for the information contained therein.